Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy

Area of Science:

• Neuroscience
• Oncology
• Molecular Biology

Background:

• Brain-specific angiogenesis inhibitor 1 (BAI1/ADGRB1) is an adhesion G protein-coupled receptor crucial for brain functions.
• BAI1 expression is reduced in brain cancers like glioblastoma (GBM), indicating its role as a tumor suppressor.
• Restoring BAI1 expression inhibits tumor growth and angiogenesis.

Purpose of the Study:

• To review the structure, function, and therapeutic applications of BAI1 in cancer treatment.
• To explore the potential of oncolytic virus (OV) therapy in restoring BAI1 expression for anti-cancer effects.

Main Methods:

• Review of existing literature on BAI1 structure, function, and expression in cancer.
• Analysis of studies utilizing oncolytic herpes simplex viruses (oHSVs) engineered to express BAI1's secreted fragment, Vasculostatin (Vstat120).
• Examination of combination therapies involving Vstat120-expressing oHSVs and chemotherapeutic agents.

Main Results:

• BAI1 plays key roles in phagocytosis, synaptogenesis, and angiogenesis inhibition.
• Restoration of BAI1 expression in cancer cells reduces tumor growth and angiogenesis.
• Vstat120-expressing oHSVs demonstrate potent anti-tumor and anti-angiogenic effects in various models.
• Combination therapies enhance anti-tumor efficacy.

Conclusions:

• BAI1 is a significant tumor suppressor with therapeutic potential in oncology.
• Oncolytic virus therapy, specifically using Vstat120-expressing oHSVs, offers a promising strategy for cancer treatment.
• Combined therapeutic approaches may improve overall anti-cancer efficacy.